PILOT-STUDY AND RANDOMIZED TRIAL OF MITOXANTRONE AND IFOSFAMIDE FOR RELAPSED NON-HODGKINS-LYMPHOMA

被引：6

作者：

PRESCOTT, RJ ^{[1
]}

LEONARD, RCF ^{[1
]}

ALLAN, NC ^{[1
]}

ANGUS, B ^{[1
]}

BARRETT, A ^{[1
]}

DAS, SN ^{[1
]}

DAWSON, AA ^{[1
]}

HEPPLESTON, A ^{[1
]}

LESSELLS, AM ^{[1
]}

LUCIE, NP ^{[1
]}

LUCRAFT, HH ^{[1
]}

MACKIE, MJ ^{[1
]}

MACLAREN, KS ^{[1
]}

MATHESON, LM ^{[1
]}

PARKER, AC ^{[1
]}

PROCTOR, SJ ^{[1
]}

SARKAR, TK ^{[1
]}

SOUKOP, M ^{[1
]}

STEWARD, WP ^{[1
]}

WHITE, JM ^{[1
]}

机构：

[1] UNIV EDINBURGH,SCH MED,SCOTTISH CANC TRIALS OFF,TEVIOT PL,EDINBURGH EM8 9AG,SCOTLAND

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷 / 1-2期

关键词：

PILOT STUDY; RANDOMIZED TRIAL; MITOXANTRONE; IFOSFAMIDE; RELAPSE; NON-HODGKINS LYMPHOMA;

D O I：

10.3109/10428199309054737

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This report compares a pilot study followed by a trial of the combination of mitozantrone and ifosfamide for relapsed lymphoma. In the pilot study (15 patients) toxicity and activity of the combination was tested on a variety of relapsed non-Hodgkin's lymphoma. In the trial (19 patients) the therapy was confined to patients with high and intermediate grade non-Hodgkin's lymphoma in which the combination was compared against single agent mitozantrone. The median survival of patients on the pilot and trial was very poor at around six months, but some individuals survived for several years from both groups. The main toxicities of treatment were, predictably, nausea and vomiting and bone marrow suppression on the combination, and bone marrow suppression alone on the single agent mitozantrone. There was no obvious disadvantage of the single agent treatment when compared with the combination, but this statement has to be interpreted with caution given the high death rate amongst all patients and the very small numbers who entered the randomised trial.

引用

页码：111 / 114

页数：4

共 50 条

[21] EPIDEMIOLOGY OF NON-HODGKINS-LYMPHOMA - A REVIEW [J].

GREINER, TC .

DIAGNOSTIC ONCOLOGY, 1994, 4 (01) :26-32

[22] NON-HODGKINS-LYMPHOMA INVOLVING THE BREAST [J].

ARBER, DA ;

SIMPSON, JF ;

WEISS, LM ;

RAPPAPORT, H .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1994, 18 (03) :288-295

[23] PHASE-2 STUDY OF MITOZANTRONE IN COMBINATION WITH CHLORAMBUCIL AND PREDNISOLONE FOR RELAPSED AND REFRACTORY NON-HODGKINS-LYMPHOMA [J].

JONES, L ;

COTTER, FE ;

LORD, D ;

NEWLAND, AC .

HEMATOLOGICAL ONCOLOGY, 1990, 8 (01) :41-45

[24] NON-HODGKINS-LYMPHOMA AND KLINEFELTER SYNDROME [J].

ATTARDMONTALTO, SP ;

SCHULLER, I ;

LASTOWSKA, MA ;

GIBBONS, B ;

KINGSTON, JE ;

EDEN, OB .

PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1994, 11 (02) :197-200

[25] PRIMARY NON-HODGKINS-LYMPHOMA OF THE THYROID [J].

JUNOR, EJ ;

PAUL, J ;

REED, NS .

EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1992, 18 (04) :313-321

[26] AUTOIMMUNE PHENOMENA IN NON-HODGKINS-LYMPHOMA [J].

GRONBAEK, K ;

DAMORE, F ;

SCHMIDT, K .

LEUKEMIA & LYMPHOMA, 1995, 18 (3-4) :311-316

[27] PRIMARY COLORECTAL NON-HODGKINS-LYMPHOMA [J].

BUSCH, E ;

RODRIGUEZBIGAS, M ;

MAMOUNAS, E ;

BARCOS, M ;

PETRELLI, NJ .

ANNALS OF SURGICAL ONCOLOGY, 1994, 1 (03) :222-228

[28] NON-HODGKINS-LYMPHOMA OF THE SPERMATIC CORD [J].

MOLLER, MB .

ACTA HAEMATOLOGICA, 1994, 91 (02) :70-72

[29] LOMUSTINE, ETOPOSIDE, METHOTREXATE AND PREDNISONE (LEMP) THERAPY FOR RELAPSED AND REFRACTORY NON-HODGKINS-LYMPHOMA [J].

DORIGO, A ;

MANSBERG, R ;

KWAN, YL .

EUROPEAN JOURNAL OF HAEMATOLOGY, 1993, 50 (01) :37-40

[30] E-SHAP - AN EFFECTIVE TREATMENT IN SELECTED PATIENTS WITH RELAPSED NON-HODGKINS-LYMPHOMA [J].

EZZAT, AA ;

KHALIFA, F ;

BERRY, J ;

KHAN, B ;

RAJA, MA ;

ABDELWARITH, A .

ANNALS OF ONCOLOGY, 1994, 5 (05) :453-456

← 1 2 3 4 5 →